CraigHMoskowitzMD

Oncology • Miami, FL

Hematologic Oncology

Physician in Chief, Oncology Service Line Sylvester Comprehensive Cancer Center

Join to view full profile

Dr. Moskowitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moskowitz's full profile

Already have an account?

Office
1120 NW 14th St
Don Soffer Clinical Research Center, 660E
Miami, FL 33136

Summary

Dr. Craig Moskowitz is an oncologist in Miami, FL and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center, NYC Health + Hospitals / Bellevue, and University of Miami Hospital and Clinics. He received his medical degree from Wayne State University School of Medicine and has been in practice 29 years. He specializes in hematologic oncology and is experienced in hematologic oncology, diffuse large b-cell lymphoma, hodgkin's lymphoma, hodgkin disease, and mantle cell.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1988 - 1992
Wayne State University School of MedicineClass of 1988

Certifications & Licensure

FL State Medical License 2018 - 2026
NY State Medical License 1989 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2012-2014
Super Doctor SuperDoctors.com

Clinical Trials

Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1995 Sep 01
Completed
Phase 2
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma Start of enrollment: 1997 Jan 01
Completed
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma Start of enrollment: 1999 Nov 01
Completed
Phase 2
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2004 Apr 01
Completed
Phase 2
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2006 Nov 28
Completed
Phase 2
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma Start of enrollment: 2006 May 01
Unknown status
Phase 1, Phase 2
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma Start of enrollment: 2007 Oct 01
Completed
Phase 2
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma Start of enrollment: 2007 Nov 13
Completed
Phase 2
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL Start of enrollment: 2003 Oct 01
Completed
Phase 2
Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma Start of enrollment: 2008 Jun 01
Completed
Phase 2
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma Start of enrollment: 2008 Jul 01
Completed
Phase 2
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) Start of enrollment: 2010 Apr 30
Completed
Phase 3
A Safety Study of SGN-CD19A for B-Cell Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma Start of enrollment: 2013 May 01
Active, not recruiting
Not Applicable
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2015 Apr 22
Completed
Phase 1, Phase 2
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma Start of enrollment: 2016 Feb 01
Terminated
Phase 1
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma Start of enrollment: 2020 Sep 22
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

496 citations
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand, Margaret A. Shipp, Vincent Ribrag, Jean-Marie Michot, Pier Luigi Zinzani
Journal of Clinical Oncology. 2016-10-23
689 citations
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert W. Chen, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie A. Johnson
Journal of Clinical Oncology. 2017-07-01
508 citations
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA)...
Craig H. Moskowitz, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki
Lancet. 2015-05-09

Journal Articles

Five-Year PFS from the AETHERA Trial of Brentuximab Vedotin for Hodgkin Lymphoma at High Risk of Progression or Relapse
Patrick Stiff, Edward Agura, Craig H Moskowitz, John Sweetenham, Auayporn Nademanee, Veronika Bachanova, Blood
CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET
David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood

Lectures

Survival for Relapsed/Refractory Hodgkin Lymphoma Patients with Recurrent or Persistent Disease Following Autologous Hematopoietic Stem Cell Transplantation Treated in...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition - Tip SheetNovember 13th, 2024
Sylvester Cancer Researchers Share Findings in Oral Presentations at the ASH 2024 Annual Meeting & Exposition – Tip SheetNovember 13th, 2024
Blood Cancer Patients to Be Offered Groundbreaking New Immunity Drugs as ‘Standard of Care’ on the NHS After Success of Trial in Patients Who Failed to Respond to Other DrugsMay 4th, 2024
Join now to see all